KR102052522B1 - Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides - Google Patents
Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides Download PDFInfo
- Publication number
- KR102052522B1 KR102052522B1 KR1020130109335A KR20130109335A KR102052522B1 KR 102052522 B1 KR102052522 B1 KR 102052522B1 KR 1020130109335 A KR1020130109335 A KR 1020130109335A KR 20130109335 A KR20130109335 A KR 20130109335A KR 102052522 B1 KR102052522 B1 KR 102052522B1
- Authority
- KR
- South Korea
- Prior art keywords
- green tea
- polysaccharide
- ginseng
- present
- polysaccharides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an antioxidant composition containing ginseng polysaccharide and green tea polysaccharide, and more particularly, to a composition for reducing skin wrinkles and enhancing elasticity by providing an excellent antioxidant effect by using a mixture of ginseng polysaccharide and green tea polysaccharide. will be.
Description
The present invention relates to an antioxidant composition containing ginseng polysaccharide and green tea polysaccharide, and more particularly, to a composition for reducing skin wrinkles and enhancing elasticity by providing an excellent antioxidant effect by using a mixture of ginseng polysaccharide and green tea polysaccharide. will be.
Reactive oxygen species (ROS) are involved in the aging of the skin is well known by many studies. The oxygen oxidative theory of aging was proposed by Harman in 1956, suggesting that oxidative damage to bioconstituents is caused by various free radicals, which are generated by incidental metabolic processes, and these damages accumulate and lead to aging and death. will be. Damages caused by free radicals are handled by the body's defense ability, but since the defense is not 100% complete, some of the free radicals are adversely affected. This adverse action occurs slowly and, in some cases, for years or even throughout life, and accumulates, degrading the function of cells and tissues in the skin, which causes disease and aging.
Expression of inflammation is a series of reactions to maintain homeostasis in the body, but clinically, redness, swelling, fever, pain and dysfunction may appear. Histologically, the site of inflammation can be seen in the infiltration of neutrophils, monocytes, neutrophils, monocytes, as well as necrosis of cells, expansion of capillaries and edema. However, these phenomena do not occur simultaneously, but appear in a sequence of orders. In recent years, many chemical mediators (chemical mediators) and their actions are known. The process of inflammation is divided into three stages: hemodynamic changes due to changes in blood flow and blood vessel size, exudation of inflammatory cells, and proliferation of connective tissue. Among these, the part being studied in relation to ROS is hemodynamic variation.
In inflammation, platelet activating factor (PAF) is secreted to increase the permeability of blood vessels, increase nitric oxide synthesis, expand blood vessels, express adhesion molecules and participate in the attachment and migration of white blood cells. In addition, during acute inflammation, the surface properties of endothelial cells change. There is a lot of research that relates the above series of reactions and ROS.
As such, antioxidants are essential in living organisms. If you consume antioxidants as food or supplements, it is not easy to reach your skin. The skin surrounds the outermost part of the human body and is a peripheral organ that is in direct contact with the external environment and harmful factors such as ultraviolet rays, but is not directly related to life. Therefore, when the body lacks vitamins or antioxidants, the skin becomes deficient first. easy. In other words, from the point of view of the human body and organs such as the five organs to supply the necessary ingredients first to survive and then send the remaining to the skin. Therefore, it is necessary to give antioxidant power to the skin.
Therefore, if the anti-oxidation effect is implemented in the skin, it will satisfy the customers' demand for skin anti-oxidation for cosmetics and will be very popular in various effects on skin aging, especially antioxidant, skin wrinkle and elasticity improving effect.
Thus, the present inventors attempted to find a substance having excellent antioxidant efficacy among natural extracts to solve the above problems, and when using the ginseng polysaccharide derived from ginseng and green tea polysaccharide derived from green tea at the same time, it provides excellent antioxidant power by synergistic effect. It was confirmed that this can be done, and this invention was completed.
Therefore, an object of the present invention is to provide a composition that can provide excellent antioxidant effect by using both ginseng polysaccharide and green tea polysaccharide simultaneously, and consequently delay skin aging.
In order to achieve the above object, the present invention provides a skin external composition or pharmaceutical composition for antioxidant containing ginseng polysaccharide and green tea polysaccharide as an active ingredient.
The composition of the present invention provides excellent antioxidant efficacy by containing ginseng polysaccharide and green tea polysaccharide, thereby reducing skin wrinkles and enhancing elasticity and consequently delaying skin aging.
The composition of the present invention provides an excellent antioxidant effect by containing ginseng polysaccharide and green tea polysaccharide as active ingredients.
The ginseng (Panax ginseng CA Meyer) polysaccharide used in the present invention is a pectin-like substance having a molecular weight of 34,600, and contains about 60% of galacturonic acid. Galactose and the like constitute a side chain. Ginseng used in the present invention is a plant belonging to the genus Ogapi and ginseng, ginseng in the present invention can be used without limitation in its kind and annual root, can be used both ginseng and dried. In addition, ginseng in the present invention can be used without limitation in the area, specifically, the root of ginseng can be used.
In addition, the green tea polysaccharide used in the present invention is derived from green tea, and unlike the polysaccharides found in other plants, it is an acidic polysaccharide group, and is produced by combining sugar components and amino acids made through photosynthesis. Green tea in the present invention can be used without limitation in the type and cultivation days, it is possible to use both dried or not dried green tea. In addition, the green tea in the present invention can be used without limitation, specifically, the leaves of green tea can be used.
Ginseng polysaccharide and green tea polysaccharide used in the present invention may be prepared by a method known in the art, the method is not particularly limited.
Specifically, after preparing ginseng root or green tea leaf extract with water at 38-42 ° C., and concentrating it, removing impurities with a filter, and then adding ethanol and hot air drying, green tea polysaccharide and ginseng polysaccharide can be obtained. .
The composition of the present invention may contain a ginseng polysaccharide and a green tea polysaccharide in an amount of 0.001 to 10% by weight based on the total weight of the composition, respectively, preferably a ginseng polysaccharide and green tea polysaccharide to 0.005 to 9.5% by weight, respectively , 0.01-9%, 0.03-8.5%, 0.05-8%, 0.07-7.5%, 0.09-7%, 0.1-6.5%, 0.3-6%, 0.5-5.5% or 0.7 It may be contained in an amount of ˜5 wt%.
In the present invention, ginseng polysaccharide and green tea polysaccharide are used by mixing in the range of 0.1 to 10: 1 by weight. In addition, in order to maximize the synergistic effect of the combination of the two components, preferably used to mix the ginseng polysaccharide and green tea polysaccharide in the range of 0.5 to 9.5: 1, 1 to 9: 1 or 1.5 to 8.5: 1 by weight ratio Can be.
The composition of the present invention may be formulated as an external composition for skin, in particular a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base. In addition, the compositions of the present invention may be provided in all formulations suitable for topical application, for example, emulsions obtained by dispersing the oil phase in a solution, aqueous phase, emulsions obtained by dispersing the aqueous phase in oil phase, suspensions, solids, gels, powders, It may be provided in the form of a paste, foam or aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
In addition, the composition according to the present invention may include other ingredients in addition to the above-mentioned materials within a range not impairing the main effect, preferably a synergistic effect on the main effect. In addition, the composition according to the present invention may further include a moisturizer, an emulsifier, a UV absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavoring, cooling agent or limiting agent. The blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight relative to the total weight of the composition. .
In addition, the compositions of the present invention may be formulated as pharmaceutical compositions. When the composition according to the present invention is applied to a pharmaceutical product, it may be formulated as an oral or parenteral dosage form in the form of a solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier to the active ingredient used in the present invention. , The pharmaceutical composition according to the invention can be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
Formulations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups, pellets and the like. In addition, the formulation for parenteral administration includes injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to the present invention can be easily formulated by carrying out according to a conventional method, and at this time, surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspending agents, and other commercially available auxiliaries can be suitably used. have.
The dosage of the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Determination of a suitable dose based on these factors is within the level of one of skill in the art and its daily dosage may be, for example, 0.1 mg / kg / day to 100 mg / kg / day, more specifically 5 mg / kg / day to 50 mg / kg. May be, but is not limited to.
Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
Reference Example 1 Preparation of Ginseng Polysaccharide
1 kg of dried white ginseng was pulverized with a blender, and 10 liters of purified water was added thereto, stirred and extracted with 38-42 ° C. hot water for 24 hours, and then deposited at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The separated filtrate was concentrated under reduced pressure to 1/10 the amount of purified water. To this was added dropwise ethanol in a concentrated amount of 4 times and hot air dried to obtain 65 g of ginseng polysaccharide.
Reference Example 2 Preparation of Green Tea Polysaccharide
1 kg of the first processed green tea leaves were pulverized with a blender, and then 10 liters of purified water was added thereto, stirred and extracted with hot water at 38-42 ° C. for 24 hours, and then deposited at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation. The separated filtrate was concentrated under reduced pressure to 1/10 the amount of purified water. To this was added dropwise four times the concentrated ethanol and hot air dried to obtain 72g of green tea polysaccharide.
Example 1 Preparation of a Mixture of Ginseng Polysaccharide and Green Tea Polysaccharide
The ginseng polysaccharide prepared in Reference Example 1 and the green tea polysaccharide prepared in Reference Example 2 were mixed at a ratio of 1: 3.
Example 2 Preparation of Mixture of Ginseng Polysaccharide and Green Tea Polysaccharide
The ginseng polysaccharide prepared in Reference Example 1 and the green tea polysaccharide prepared in Reference Example 2 were mixed at a ratio of 1: 1.
Example 3 Preparation of Mixture of Ginseng Polysaccharide and Green Tea Polysaccharide
The ginseng polysaccharide prepared in Reference Example 1 and the green tea polysaccharide prepared in Reference Example 2 were mixed at a ratio of 3: 1.
Test Example 1 Inhibitory Effect of Reactive Oxygen Species Production
The keratinocytes (F1eratinocyte) isolated from the skin tissue of the person into a 5 × 10 4 are in each well of a 24-well plate was attached for 24 hours. After 16 hours, the materials of Examples 1 to 3 and Reference Examples 1 and 2 were each treated with 1%. At this time, the control did not process anything for comparison. After 2 hours, the culture solution was removed, and 100 µl of phosphate buffered saline (PBS) was added to each well. The keratinocytes were irradiated with UV 30 mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: F15T8, UV B 15 W, SanF1yo DennF1i, Japan), and then PBS was removed and each cell was prepared with keratinocyte culture solution 200. Μl was added. Here, the test materials of Examples 1 to 3 and Reference Examples 1 to 2 were again treated, and the amount of reactive oxygen species increased by ultraviolet stimulation at regular time intervals was quantified. The amount of ROS was quantified by referring to Tan's method for measuring the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432). Table 1 shows the results of calculating the ratio of the vehicle-treated control group ROS.
In the results of Table 1, the ginseng polysaccharide and the green tea polysaccharide used in the present invention inhibits the production of ROS known to cause skin cell damage by ultraviolet rays, and is particularly a mixture of the ginseng polysaccharide and the green tea polysaccharide. In addition, it is possible to confirm that the antioxidant activity is very excellent by inhibiting the generation of ROS very effectively, and inhibiting the generation of ROS to a level almost similar to the case of not irradiating UV light after the stimulation of UV light.
Therefore, it can be seen that the mixture of ginseng polysaccharide and green tea polysaccharide used in the present invention can help to prevent and improve skin aging by inhibiting oxidation and defending the production of skin irritation.
Test Example 2 Measurement of Collagenase Expression Inhibition Efficacy
Inhibition of collagenase production of Examples 1 to 3 and Reference Examples 1 to 2 was measured by comparing with tocopherols and EGCG as controls.
Human fibroblasts (Human Dermal Fibroblasts, neonatal (HDFn)) in 96-well plates containing DMEM (Dulbecco's Modified Eagle's Media) medium containing 2.5% fetal calf serum (lot # 617766, Cascade Biologics Inc.). , Portland, Oregon (OR) USA) was added to 5,000 cells / well (well), and cultured until 90% growth. After culturing in serum-free DMEM medium for 24 hours, the serum-free DMEM medium was treated with the test materials of Examples 1 to 3 and Reference Examples 1 to 2 at a molar concentration of 10 -4 for 24 hours. Was collected.
The collected cell culture medium was measured for collagenase production using a commercially available collagenase measuring instrument (Amersham Pharma Co., Ltd., USA). First, the cultured cells were placed in 96-well plates uniformly coated with primary collagenase antibodies, and antigen-antibody reactions were performed in a thermostat for 3 hours.
After 3 hours, the secondary collagen antibody conjugated with the chromophore was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.
The absorbance of the yellow-colored 96 well plate was measured at 405 nm using an absorbance meter, and the degree of synthesis of collagenase was calculated by Equation 1 below. At this time, the reaction absorbance of the prepared cell culture medium of the group not treated with the composition was used as a control.
The results of measuring the collagenase expression inhibitory effect of the test substances in the human fibroblasts are shown in Table 2 below the degree of collagenase expression, which is prepared by comparing the collagenase expression level of the untreated group to 100. .
Looking at Table 2, it can be seen that the mixture of ginseng polysaccharide and green tea polysaccharide used in the present invention inhibits collagenase expression in vitro.
In addition, as shown in Table 1, each of Examples 1 to 3 is not only superior to collagenase inhibitory effect than Reference Examples 1 to 2, but also significantly higher collagenase expression than tocopherol, a positive control group. It can be seen that the effect.
Test Example 3 Procollagen Production Promoting Effect Experiment
The procollagen producing ability of Examples 1 to 3 and Reference Examples 1 to 2 was measured by comparing with vitamin C.
Place human fibroblasts at 5,000 cells / well in 96-well plates containing DMEM (Dulbecco's Modified Eagle's Media) containing 2.5% fetal calf serum and incubate until 90% growth It was. Thereafter, the cells were incubated for 24 hours in serum-free DMEM medium, and then the test materials of Examples 1 to 3 and Reference Examples 1 and 2 dissolved in serum-free DMEM medium, and vitamin C for 10 hours at 10 -4 molar concentration, respectively. After treatment, cell culture fluid was collected. After 24 hours, the amount of free collagen in the medium was measured using the procollagen type-1 C-peptide EIA kit (MK101, Takara, Japan).
The degree of procollagen production in the untreated group was set to 100, and the degree of procollagen production in the group treated with the test substance was determined, and the results are shown in Table 3 below.
Looking at Table 3, it can be seen that the mixture of ginseng polysaccharide and green tea polysaccharide used in the present invention promotes production of procollagen in vitro.
In addition, Examples 1 to 3 is not only significantly superior to the effect of promoting the production of procollagen than Reference Examples 1 to 2, it can be confirmed that the effect is equivalent to the vitamin C of the positive control group.
From this, it can be seen that the mixture of ginseng polysaccharide and green tea polysaccharide used in the present invention has an excellent effect of promoting collagen production and has excellent collagen production ability, thus effectively preventing skin wrinkle formation and providing a wrinkle improvement effect. .
Test Example 4 Measurement of Elastase Activity Inhibition Effect
The elastase activity inhibitory ability of Examples 1 to 3 and Reference Examples 1 to 2 was measured by comparing with EGCG. The elastase and substrate used were purchased commercially from Sigma-Aldrich, USA (Cat.No. E0127).
Elastase activity inhibitory activity was tested by the following test method.
In a 96 well plate, 10 mg / L Tris-HCL buffer (pH 8.0) was mixed with Examples 1-3 and Reference Examples 1-2 (200 µL) and 50 µL of 20 µg / mL Elastase Type III solution, respectively. . 250 μM of EGCG was used as a positive control and distilled water was used as a non-treated group as a negative control. Thereafter, 100 µL of 0.4514 mg / mL N-SUCCINYL-ALA-ALA-ALA-p-NITROANILIDE prepared with the above buffer was added and reacted at 25 ° C for 15 minutes. After completion of the reaction, the absorbance at a wavelength of 415 nm was measured. A blank test was performed in the same manner to correct.
Calculation method of the elastase activity inhibitory activity is shown in Equation 2 below, the results are shown in Table 4.
A: Absorption at wavelength 415 nm with no test substance added and enzyme added
B: Absorbance at wavelength 415 nm with no test substance added and no enzyme added
C: absorbance at wavelength 415 nm at test substance addition and enzyme addition
D: absorbance at wavelength 415 nm with test substance added and without enzyme
Referring to Table 4, the ginseng polysaccharide or green tea polysaccharide used in the present invention inhibits elastase activity, and in particular, Examples 1 to 3, in which ginseng polysaccharide and green tea polysaccharide are mixed, have an elastase inhibitory degree. It can be seen that it is remarkably superior to EGCG known as an activity inhibitor.
[Formulation Examples 1 to 3 and Comparative Formulation Examples 1 to 3]
Nutritional cream was prepared in a conventional manner according to the composition of Table 5 (unit: wt%).
Test Example 5 Confirmation of Skin Elasticity Improvement Efficacy
In order to confirm the effect of improving skin elasticity in humans, the formulations of Examples 1 to 3 and Comparative Formulations 1 to 3 were evaluated as follows.
120 healthy women in their 30s and 40s were divided into 6 groups of 20 people and one composition was used for each group. After applying it to the face once a day for 12 weeks, the skin elasticity tester (Cutometer SEM 575, C + K) Electronic Co., Germany) was used to measure skin elasticity. The results are shown in Table 6 below. The results in Table 6 refer to the properties of skin viscoelasticity of the skin elasticity tester.
As shown in Table 6, Formulation Examples 1 to 3 and Comparative Formulation Examples 1 to 2 containing the ginseng polysaccharide or green tea polysaccharide increased skin elasticity compared to the group to which the Comparative Formulation Example 3 was applied, especially ginseng polysaccharide and green tea. Groups to which Formulation Examples 1 to 3 containing a mixture of polysaccharides were applied can confirm that the skin elasticity was significantly increased.
As described above in detail the specific parts of the present invention, it is apparent to those skilled in the art that such specific description is merely a preferred embodiment, thereby not limiting the scope of the present invention. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (10)
The mixing ratio of the ginseng polysaccharide and green tea polysaccharide in the mixture is 0.1 to 10: 1 based on the weight of the cosmetic composition for inhibiting skin wrinkles.
The mixing ratio of the ginseng polysaccharide and green tea polysaccharide in the mixture is 0.1 ~ 10: 1 cosmetic composition for improving skin elasticity based on the weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130109335A KR102052522B1 (en) | 2013-09-11 | 2013-09-11 | Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130109335A KR102052522B1 (en) | 2013-09-11 | 2013-09-11 | Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150030093A KR20150030093A (en) | 2015-03-19 |
KR102052522B1 true KR102052522B1 (en) | 2019-12-06 |
Family
ID=53024284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020130109335A KR102052522B1 (en) | 2013-09-11 | 2013-09-11 | Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102052522B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102119511B1 (en) * | 2019-12-30 | 2020-06-05 | 주식회사 다이아린 | Functional cosmetic composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100513430B1 (en) | 2002-03-19 | 2005-09-07 | 한국원자력연구소 | Cosmetic composition containing ginsan polysaccharide extracted from Panax ginseng |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100423521B1 (en) * | 2001-08-29 | 2004-03-18 | 네비온 주식회사 | Cosmetic compositions containing panax ginseng polysaccharides |
KR20100010132A (en) * | 2008-07-22 | 2010-02-01 | (주)아모레퍼시픽 | Method for preparing polysaccharide of green tea |
KR101193725B1 (en) * | 2009-10-27 | 2012-10-22 | (주)아모레퍼시픽 | Cosmetic composition for anti-inflammatory and anti-oxidation containing Green tea polysaccharide and Tricholoma matsutake extract |
KR101144991B1 (en) * | 2009-12-29 | 2012-06-27 | 대한민국 | Pharmaceutical composition and health improving food composition containing ginseng extracts for preventing or treating benign postatic hyperplasia |
-
2013
- 2013-09-11 KR KR1020130109335A patent/KR102052522B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100513430B1 (en) | 2002-03-19 | 2005-09-07 | 한국원자력연구소 | Cosmetic composition containing ginsan polysaccharide extracted from Panax ginseng |
Also Published As
Publication number | Publication date |
---|---|
KR20150030093A (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100825450B1 (en) | Skin anti-wrinkle cosmetics composition containing Forsythiae Fruit extract | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR20160125784A (en) | Shiunko fermented oil and producing method thereof | |
KR20180069756A (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR101199209B1 (en) | Cosmetic composition containing fermented extracts with salt of natural materials | |
KR101853743B1 (en) | External composition for skin containing Kalopanax pictus (Thunb.) Nakai extract | |
US20090170788A1 (en) | Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose | |
KR101204858B1 (en) | Cosmetic Composition for for improving Skin-Wrinkle | |
KR101874605B1 (en) | Skin external composition containing Calanthe discolor Lindl. extract | |
KR100762287B1 (en) | Cosmetic composition with high amount of minerals comprising deep sea water and extract of peach blossom | |
KR102052522B1 (en) | Anti-oxidating composition containing Panax ginseng polysaccharides and Green tea polysaccharides | |
KR20080093500A (en) | Cosmetic compositions for preventing skin aging comprising extract astilbe chinensis var. davidii | |
KR102337308B1 (en) | Composition for preventing or improving skin aging containing (-)-eudesmin | |
KR20160003918A (en) | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts | |
KR20090036904A (en) | Cosmetic compositions comprising prunella vulgaris extract and adenosine | |
KR101860110B1 (en) | Cosmetic composition for anti-oxidation containing Acaiberry extract and sprout extract | |
KR101398392B1 (en) | cosmetic compositions containing extract of Viburnum dilatatum Thunb used for antiwrinkle | |
KR101008833B1 (en) | cosmetic compositions containing extract of Sorbus alnifolia S. et Z. K. Koch used for antiwrinkle | |
KR100967805B1 (en) | cosmetic compositions containing extract of Ostrya japonica Sarg used for antiwrinkle | |
KR20180069755A (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR101817242B1 (en) | Skin external composition containing Glehnia littoralis Fr. Schmidt extract | |
KR20080020853A (en) | Extracts from corchorus olitorius l. and anti-inflammatory cosmetic composition including the same | |
KR102215164B1 (en) | Composition for preventing or improving skin aging containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester | |
KR20160082113A (en) | Skin external composition for anti-anging comprising compound K and panaxydol | |
JP2024088057A (en) | Type 12 collagen production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |